Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-2p87r Total loading time: 0.69 Render date: 2021-10-20T14:34:52.146Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Chapter 4 - Neuroendocrine Regulation of Appetite and Body Weight

Published online by Cambridge University Press:  24 December 2018

Michael Wilkinson
Affiliation:
Dalhousie University, Nova Scotia
S. Ali Imran
Affiliation:
Dalhousie University, Nova Scotia
Get access
Type
Chapter
Information
Clinical Neuroendocrinology
An Introduction
, pp. 53 - 74
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albuquerque, D, Nóbrega, C, Manco, L & Padez, C. (2017). The contribution of genetics and environment to obesity. Brit Med Bull 123, 159173.CrossRefGoogle ScholarPubMed
Cataletto, M, Angulo, M, Hertz, G & Whitman, B. (2011). Prader-Willi syndrome: a primer for clinicians. Int J Ped Endocr 2011, 12.CrossRefGoogle ScholarPubMed
Chakradhar, S. (2016). All in one:  researchers create combination drugs for diabetes and obesity. Nat Med 22, 694696.CrossRefGoogle ScholarPubMed
Flier, J S & Maratos-Flier, E. (2017). Leptin’s physiologic role: does the emperor of energy balance have no clothes? Cell Metab 26, 2426.CrossRefGoogle ScholarPubMed
Friedman, J. (2016). The long road to leptin. J Clin Invest 126, 47274734.CrossRefGoogle Scholar
Heymsfield, S B & Wadden, T A. (2017). Mechanisms, pathophysiology, and management of obesity. New Eng J Med 376, 254266.CrossRefGoogle ScholarPubMed
Hopkins, M, Blundell, J, Halford, J, King, N & Finlayson, G. (2016). The regulation of food intake in humans. www.endotext.org.
O’Rahilly, S & Farooqi, I S. (2008). Human obesity as a heritable disorder of the central control of energy balance. Int J Obes 32, S35S61.Google ScholarPubMed
Schwartz, M W, Seeley, R J, Zeltser, L M et al. (2017). Obesity pathogenesis: an endocrine society scientific statement. Endocr Revs 38, 267296.CrossRefGoogle Scholar
The GBD Obesity Collaborators (2017). Health effects of overweight and obesity in 195 countries over 25 years. New Eng J Med 377, 1327.CrossRef
Abel, B S, Muniyappa, R, Stratton, P, Skarulis, M C, Gorden, P & Brown, R J. (2016). Effects of recombinant human leptin (Metreleptin) on nocturnal luteinizing hormone secretion in lipodystrophy patients. Neuroendocr 103, 402407.CrossRefGoogle ScholarPubMed
Ak, M, Sezlev, D, Sutcigil, L, Akarsu, S, Ozgen, F & Yanik, T. (2013). The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy. Psychoneuroendocr 38, 341347.CrossRefGoogle ScholarPubMed
Alsalim, W, Omar, B, Pacini, G, Bizzotto, R, Mari, A & Ahrén, B. (2015). Incretin and islet hormone responses to meals of increasing size in healthy subjects. J Clin Endocr Metab 100, 561568.CrossRefGoogle ScholarPubMed
Angulo, M A, Butler, M G & Cataletto, M E. (2015). Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocr Invest 38, 12491263.CrossRefGoogle ScholarPubMed
Arango, C, Rojas, M J, Moreno, D & Parellada, M. (2002). Sibutramine for compulsive eating in hypothalamic deficiency. J Am Acad Child Adolesc Psych 41, 11471148.CrossRefGoogle ScholarPubMed
Astrup, A, Rössner, S, Van Gaal, L et al., on behalf of the NN8022-1807 Study Group. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 16061616.CrossRefGoogle ScholarPubMed
Bak, M J, Albrechtsen, N J W, Pedersen, J et al. (2014). Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab 16, 11551164.CrossRefGoogle ScholarPubMed
Bakker, N E, Wolffenbuttel, K P, Looijenga, L H & Hokken-Koelega, A C. (2015). Testes in infants with Prader-Willi syndrome: human chorionic gonadotropin treatment, surgery and histology. J Urol 193, 291298.CrossRefGoogle ScholarPubMed
Bakker, N E, Lindberg, A, Heissler, J et al. (2017). Growth hormone treatment in children with Prader-Willi syndrome: three years of longitudinal data in prepubertal children and adult height data from the KIGS Database. J Clin Endocr Metab 102, 17021711.CrossRefGoogle ScholarPubMed
Ballon, J S, Pajvani, U B, Mayer, L E S et al. (2018). Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. J Psychopharmacol 32, 533540.CrossRefGoogle ScholarPubMed
Beall, C, Hanna, L & Ellacott, K L J. (2017). CNS targets of adipokines. Compr Physiol 7, 13591406.CrossRefGoogle ScholarPubMed
Benedict, C, Axelsson, T, Söderberg, S et al. (2014). Fat mass and obesity-associated gene (FTO) is linked to higher plasma levels of the hunger hormone ghrelin and lower serum levels of the satiety hormone leptin in older adults. Diabetes 63, 39553959.CrossRefGoogle ScholarPubMed
Bray, G A & Gallagher, T F Jr. (1975). Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine 54, 301330.CrossRefGoogle Scholar
Brown, R J, Araujo-Vilar, D, Cheung, P T et al. (2016). The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocr Metab 101, 45004511.CrossRefGoogle ScholarPubMed
Carr, R D, Larsen, M O, Jelic, K et al. (2010). Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocr Metab 95, 872878.CrossRefGoogle ScholarPubMed
Çetinkaya, S, Güran, T, Kurnaz, E et al. (2018). A patient with proopiomelanocortin deficiency: an increasingly important diagnosis to make. J Clin Res Ped Endocr 10, 6873.CrossRefGoogle Scholar
Chen, K Y, Muniyappa, R, Abel, B S et al. (2015). RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocr Metab 100, 16391645.CrossRefGoogle ScholarPubMed
Chou, S C & Mantzoros, C. (2014). Role of leptin in human reproductive disorders. J Endocr 223, T49T62.CrossRefGoogle ScholarPubMed
Colldén, G, Tschöp, M H & Müller, T D. (2017). Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci 18, 798.CrossRefGoogle ScholarPubMed
Collet, T-H, Dubern, B, Mokrosinski, J et al. (2017). Evaluation of a melanocortin-4 receptor (MC4 R) agonist (Setmelanotide) in MC4 R deficiency. Mol Metab 6, 13211329.CrossRefGoogle Scholar
Considine, R V, Sinha, M K, Heiman, M L et al. (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Eng J Med 334, 292295.CrossRefGoogle ScholarPubMed
Cummings, D E, Purnell, J Q, Frayo, R S, Schmidova, K, Wisse, B E & Weigle, D S. (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 17141719.CrossRefGoogle ScholarPubMed
Currow, D, Temel, J S, Abernethy, A, Milanowski, J, Friend, J & Fearon, K C. (2017). ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 28, 19491956.CrossRefGoogle ScholarPubMed
Davenport, R J & Wright, S. (2014). Treating obesity: is it all in the gut? Drug Discov Today 19, 845858.CrossRefGoogle Scholar
Deepak, D, Furlong, N J, Wilding, J P & MacFarlane, I A. (2007). Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic–pituitary disease. Postgrad Med J 83, 277280.CrossRefGoogle ScholarPubMed
de Lind van Wijngaarden, R F, Otten, B J, Festen, D A et al. (2008). High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocr Metab 93, 16491654.CrossRefGoogle ScholarPubMed
Dhurandhar, E J. (2016). The downfalls of BMI-focused policies. Int J Obes 40, 729730.CrossRefGoogle ScholarPubMed
Dietrich, M O & Horvath, T L. (2010). Neural regulation of food intake and energy balance. Nature poster: www.nature.com/nrn/posters/feeding.
Druce, M R, Wren, A M, Park, A J et al. (2005). Ghrelin increases food intake in obese as well as lean subjects. Int J Obes 29, 11301136.CrossRefGoogle ScholarPubMed
Editorial (2017). Lancet Diabetes Endocr 5, 483.
Farholt, S, Sode-Carlsen, R, Christiansen, J S, Østergaard, J R & Høybye, C. (2011). Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocr Metab 96, E173E180.CrossRefGoogle ScholarPubMed
Farooqi, I S, Matarese, G, Lord, G M et al. (2002). Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110, 10931103.CrossRefGoogle ScholarPubMed
Farooqi, I S, Keogh, J M, Yeo, G S H, Lank, E J, Cheetham, T & O’Rahilly, S. (2003). Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. New Eng J Med 348, 10851095.CrossRefGoogle ScholarPubMed
Farooqi, I S, Wangensteen, T, Collins, S et al. (2007). Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. New Engl J Med 356, 237247.CrossRefGoogle ScholarPubMed
Farooqi, I S & O’Rahilly, S. (2014). Human disorders of leptin action. J Endocr 223, T63T70.CrossRefGoogle ScholarPubMed
Fasshauer, M & Blüher, M. (2015). Adipokines in health and disease. Trends Pharmacol Sci 36, 461470.CrossRefGoogle ScholarPubMed
Finan, B, Clemmensen, C & Müller, T D. (2015). Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Mol Cell Endocr 418, 4254.CrossRefGoogle ScholarPubMed
Fiorenza, C G, Chou, S H & Mantzoros, C S. (2011). Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocr 7, 137150.CrossRefGoogle ScholarPubMed
Frayling, T M, Timpson, N J, Weedon, M N et al. (2007). A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889894.CrossRefGoogle ScholarPubMed
Friedman, J. (2016). The long road to leptin. J Clin Invest 126, 47274734.CrossRefGoogle Scholar
Garcia, J M. (2017). What is next after anamorelin? Curr Opin Support Palliat Care 11, 266271.CrossRefGoogle ScholarPubMed
Garcia, J M & Polvino, W J. (2007). Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12, 594600.CrossRefGoogle ScholarPubMed
Garcia, J M, Boccia, R V, Graham, C D et al. (2015). Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 16, 108116.CrossRefGoogle ScholarPubMed
Gardiner, J V, Jayasena, C N & Bloom, S R. (2008). Gut hormones: a weight off your mind. J Neuroendocr 20, 834841.CrossRefGoogle ScholarPubMed
Gautier, J-F, Choukem, S-P & Girard, J. (2008). Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & Metab 34, S65S72.CrossRefGoogle ScholarPubMed
Goldstone, A P, Holland, A J, Butler, J V & Whittington, J E. (2012). Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obes 36, 15641570.CrossRefGoogle ScholarPubMed
Goodarzi, M O. (2018). Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocr 6, 223236.CrossRefGoogle ScholarPubMed
Guerra, B, Fuentes, T, Delgado-Guerra, S et al. (2008). Gender dimorphism in skeletal muscle leptin receptors, serum leptin and insulin sensitivity. PLoS ONE 3, e3466.CrossRefGoogle ScholarPubMed
Halawi, H, Khemani, D, Eckert, D et al. (2017). Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastro Hepatol 2, 890899.CrossRefGoogle ScholarPubMed
Harz, K J, Müller, H L, Waldeck, E, Pudel, V & Roth, C. (2003). Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J Clin Endocr Metab 88, 52275231.CrossRefGoogle ScholarPubMed
Haqq, A M, Farooqi, I S, O’Rahilly, S et al. (2003). Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi Syndrome. J Clin Endocr Metab 88, 174178.CrossRefGoogle ScholarPubMed
Hay, D L, Chen, S, Lutz, T A, Parkes, D G & Roth, J D. (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 67, 564600.CrossRefGoogle ScholarPubMed
Henderson, D C, Vincenzi, B, Andrea, N V, Ulloa, M & Copeland, P M. (2015). Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiat 2, 452464.CrossRefGoogle ScholarPubMed
Heymsfield, S B & Wadden, T A. (2017). Mechanisms, pathophysiology, and management of obesity. New Eng J Med 376, 254266.CrossRefGoogle ScholarPubMed
Heymsfield, S B, Greenburg, A S, Fujioka, K et al. (1999). Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282, 15681575.CrossRefGoogle ScholarPubMed
Hosojima, H, Togo, T, Odawara, T et al. (2006). Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20, 7579.CrossRefGoogle ScholarPubMed
Hotta, M, Ohwada, R, Akamizu, T, Shibasaki, T & Kangawa, K. (2012). Therapeutic potential of ghrelin in restricting-type anorexia nervosa. Methods Enzymol 514, 381398.CrossRefGoogle ScholarPubMed
Igaki, N, Tanaka, M & Goto, T. (2005). Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. Intern Med 44, 832837.CrossRefGoogle Scholar
Inge, T H, Pfluger, P, Zeller, M et al. (2007). Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract Endocr Metab 3, 606609.CrossRefGoogle ScholarPubMed
Irizarry, K A, Miller, M, Freemark, M & Haqq, A M. (2016). Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Ped 63, 4777.CrossRefGoogle Scholar
Ismail, D, O’Connell, M A & Zacharin, M R. (2006). Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Ped Endocr Metab 19, 129134.CrossRefGoogle ScholarPubMed
Karra, E, O’Daly, O G, Choudhury, A I et al. (2013). A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest 123, 35393551.CrossRefGoogle ScholarPubMed
Kleinert, M, Clemmensen, C, Stemmer, K, Müller, T D, DiMarchi, R D & Tschöp, M H. (2017). Emerging poly-agonists for obesity and type 2 diabetes. Obesity 25, 16471649.CrossRefGoogle ScholarPubMed
Krude, H, Biebermann, H, Luck, W, Horn, R, Brabant, G & Grüters, A. (1998). Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Gen 19, 155157.CrossRefGoogle ScholarPubMed
Krude, H & Grüters, A. (2000). Implications of pro-opiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocr Metab 11, 1522.CrossRefGoogle ScholarPubMed
Kühnen, P, Clément, K, Wiegand, S et al. (2016). Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. New Eng J Med 375, 240246.CrossRefGoogle ScholarPubMed
Kyriakidis, M, Caetano, L, Anastasiadou, N, Karasu, T & Lashen, H. (2016). Functional hypothalamic amenorrhoea: leptin treatment, dietary intervention and counselling as alternatives to traditional practice – systematic review. Europ J Obstet Gynecol Reprod Biol 198, 131137.CrossRefGoogle ScholarPubMed
Licinio, J, Caglayan, S, Ozata, M et al. (2004). Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 101, 45314536.CrossRefGoogle ScholarPubMed
Lippl, F, Erdmann, J, Steiger, A et al. (2012). Low-dose ghrelin infusion – evidence against a hormonal role in food intake. Regul Peptides 174, 2631.CrossRefGoogle ScholarPubMed
Locke, A E, Kahali, B, Berndt, S et al. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197206.CrossRefGoogle ScholarPubMed
Loos, R J F & Yeo, G S H. (2014). The bigger picture of FTO – the first GWAS-identified obesity gene. Nat Revs Endocr 10, 5161.CrossRefGoogle ScholarPubMed
Lu, M L, Wang, T N, Lin, T Y et al. (2015). Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 58, 4750.CrossRefGoogle ScholarPubMed
Maffetone, P B, Rivera-Dominguez, I & Laursen, P B. (2017). Overfat adults and children in developed countries: the public heath importance of identifying excess body fat. Front public health 5, Article # 190.CrossRefGoogle Scholar
Mancini, M C & de Melo, M E. (2017). The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetol Metab Syndrom 9, 44.CrossRefGoogle ScholarPubMed
Mendiratta, M S, Yang, Y, Balazs, A E et al. (2011). Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation. Int J Ped Endocr 2011: 5.CrossRefGoogle ScholarPubMed
Messidoro, C, Elte, J W F, Cabezas, M C, van Agteren, M, Lacroix, A & de Herder, W W. (2009). Food-dependent Cushing’s syndrome. Netherlands J Med 67, 187190.Google ScholarPubMed
Morton, G M, Meek, T H & Schwartz, M W. (2014). Neurobiology of food intake in health and disease. Nat Revs Neurosci 15, 367378.CrossRefGoogle ScholarPubMed
Müller, T D, Tschöp, M H & O’Rahilly, S. (2016). Metabolic precision medicines: curing POMC deficiency. Cell Metab 24, 194195.CrossRefGoogle ScholarPubMed
Musso, C, Cochran, E, Javor, E, Young, J, DePaoli, A M & Gorden, P. (2005). The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metab Clin Exp 54, 255263.CrossRefGoogle ScholarPubMed
Myers, M G, Jr., Leibel, R L, Seeley, R J & Schwartz, M W. (2010). Obesity and leptin resistance: distinguishing cause from effect. Trends Endocr Metab 21, 643651.CrossRefGoogle ScholarPubMed
NCD Risk Factor Collaboration (NCD-RisC). (2017). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 390, 26272642.CrossRef
Ozsu, E, Ceylaner, S & Onay, H. (2017). Early-onset severe obesity due to complete deletion of the leptin gene in a boy. J Ped Endocr Metab 30, 12271230.CrossRefGoogle Scholar
Paz-Filho, G, Mastronardi, C A & Licinio, J. (2015). Leptin treatment: facts and expectations. Metab Clin Exp 64, 146156.CrossRefGoogle ScholarPubMed
Pigeyre, M, Yazdi, F T, Kaur, Y & Meyre, D. (2016). Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci 130, 943986.CrossRefGoogle ScholarPubMed
Pi-Sunyer, X, Astrup, A, Fujioka, K et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New Engl J Med 373, 1122.CrossRefGoogle ScholarPubMed
Ravussin, E, Smith, S R, Mitchell, J A et al. (2009). Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17, 17361743.CrossRefGoogle ScholarPubMed
Rehfeld, J F. (2017). The changing concept of gut endocrinology. Endocr Develop 32, 819.CrossRefGoogle ScholarPubMed
Reitman, M L. (2016). Hormone-replacement therapy for melanocyte-stimulating hormone deficiency. New Eng J Med 375, 278279.CrossRefGoogle ScholarPubMed
Rhea, E M, Salameh, T S, Logsdon, A F, Hanson, A J, Erickson, M A & Banks, W A. (2017). Blood-brain barriers in obesity. AAPS 19, 921930.CrossRefGoogle ScholarPubMed
Roth, C L, Eslamy, H, Werny, D et al. (2015). Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity 23, 12261233.CrossRefGoogle ScholarPubMed
Sahin-Efe, A, Upadhyay, J, Ko, B-J et al. (2017). Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: a cross sectional and a prospective case-control study nested in the normative aging study. Metab 79, 2432.CrossRefGoogle Scholar
Schorr, M & Miller, K K. (2017). The endocrine manifestations of anorexia nervosa: mechanisms and management. Nat Revs Endocr 13, 174186.CrossRefGoogle ScholarPubMed
Schultes, B, Ernst, B, Schmid, F & Thurnheer, M. (2009). Distal gastric bypass surgery for the treatment of hypothalamic obesity after childhood craniopharyngioma. Eur J Endocr 161, 201206.CrossRefGoogle ScholarPubMed
Schwartz, M W & Morton, G J. (2002). Obesity: keeping hunger at bay. Nature 418, 595597.CrossRefGoogle ScholarPubMed
Schwartz, M W, Seeley, R J, Zeltser, L M et al. (2017). Obesity pathogenesis: An endocrine society scientific statement. Endocr Revs 38, 267296.CrossRefGoogle Scholar
Scuteri, A, Sanna, S, Chen, W-M et al. (2007). Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 3, e115.CrossRefGoogle ScholarPubMed
Speakman, J R. (2015). The ‘Fat Mass and Obesity Related’ (FTO) gene: mechanisms of impact on obesity and energy balance. Curr Obes Rep 4, 7391.CrossRefGoogle ScholarPubMed
Spiegel, K, Tasali, E, Leproult, R, Scherberg, N & Van Cauter, E. (2011). Twenty-four-hour profiles of acylated and total ghrelin: relationship with glucose levels and impact of time of day and sleep. J Clin Endocr Metab 96, 486493.CrossRefGoogle ScholarPubMed
Steinert, R E, Feinle-Bisset, C, Asarian, L, Horowitz, M, Beglinger, C & Geary, N. (2017). Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97, 411463.CrossRefGoogle ScholarPubMed
Stunkard, A J, Harris, J R, Pedersen, N L & McClearn, G E. (1990). The body mass index of twins who have been reared apart. N Engl J Med 322, 14831487.CrossRefGoogle ScholarPubMed
Tam, C S, Lecoultre, V & Ravussin, E. (2011). Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 11, 16771685.CrossRefGoogle ScholarPubMed
Tan, T, Behary, P, Tharakan, G et al. (2017). The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers. J Clin Endocr Metab 102, 23642372.CrossRefGoogle ScholarPubMed
The GBD Obesity Collaborators (2017). Health effects of overweight and obesity in 195 countries over 25 years. New Eng J Med 377, 1327.CrossRef
Thondam, S K, Cuthbertson, D J, Aditya, B S, MacFarlane, I A, Wilding, J P & Daousi, C. (2012). A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin Endocr 77, 635637.CrossRefGoogle ScholarPubMed
Tomiyama, A J, Hunger, J M, Nguyen-Cuu, J & Wells, C. (2016). Misclassification of cardiometabolic health when using body mass index categories in NHANES 2005–2012. Int J Obes 40, 883886.CrossRefGoogle ScholarPubMed
Tschöp, M, Weyer, C, Tataranni, P A, Devanarayan, V, Ravussin, E & Heiman, M L. (2001). Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707709.CrossRefGoogle ScholarPubMed
Tschöp, M H, Finan, B, Clemmensen, C et al. (2016). Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab 24, 5162.CrossRefGoogle ScholarPubMed
Tung, Y C L, Yeo, G S H, O’Rahilly, S & Coll, A P. (2014). Obesity and FTO: changing focus at a complex locus. Cell Metab 20, 710718.CrossRefGoogle Scholar
Uher, R & Treasure, J. (2005). Brain lesions and eating disorders. J Neurol Neurosurg Psych 76, 852857.CrossRefGoogle ScholarPubMed
Valette, M, Bellisle, F, Carette, C et al. (2013). Eating behaviour in obese patients with melanocortin-4 receptor mutations: a literature review. Int J Obes 37, 10271035.CrossRefGoogle ScholarPubMed
Valette, M, Poitou, C, Kesse-Guyot, E et al. (2014). Association between melanocortin-4 receptor mutations and eating behaviors in obese patients: a case–control study. Int J Obes 38, 883885.CrossRefGoogle ScholarPubMed
Wabitsch, M, Funcke, J-B, Lennerz, B et al. (2015). Biologically inactive leptin and early-onset extreme obesity. New Engl J Med 372, 4854.CrossRefGoogle ScholarPubMed
World Obesity Federation (2017). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Revs 18, 715723.CrossRef
Yang, Q, Xiao, T, Guo, J & Su, Z. (2017). Complex relationship between obesity and the fat mass and obesity locus. Int J Biol Sci 13, 615629.CrossRefGoogle ScholarPubMed
Yeo, G S H. (2017). Genetics of obesity: can an old dog teach us new tricks? Diabetologia 60, 778783.CrossRefGoogle ScholarPubMed
Yi, X, Yuan, D, Farr, S A, Banks, W A, Poon, C-D & Kabanov, A V. (2014). Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity. J Control Release 191, 3446.CrossRefGoogle ScholarPubMed
Zelissen, P M J, Stenlof, K, Lean, M E J, Fogteloo, J, Keulen, E T P, Wilding, J. (2005). Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 7, 755761.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×